New developments in the management of advanced melanoma - role of pembrolizumab

Giuseppina Improta, Isabella Leone, Marco Donia, Stefania Gieri, Giuseppe Pelosi, Filippo Fraggetta

15 Citationer (Scopus)


Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma.
TidsskriftOncoTargets and Therapy
Sider (fra-til)2535-43
Antal sider9
StatusUdgivet - 2015


Dyk ned i forskningsemnerne om 'New developments in the management of advanced melanoma - role of pembrolizumab'. Sammen danner de et unikt fingeraftryk.